Due to maintenance our website might be slower to respond than usual today. We apologise for the inconvenience.
This document provides advice on the use of pharmacokinetic studies in paediatric drug development and on methodological issues concerning pharmacokinetic studies in paediatric patients.
Keywords: Children, extrapolation, dose finding, maturation, age, adolescents, newborns, infants, toddlers, pharmacokinetics
Current effective version
Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population
English (EN) (114.35 KB - PDF)
Document history - Revision 1
Concept paper on the revision of the guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population
The guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population was adopted by the European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP) in 2006 with the aim of aiding paediatric drug development. The Paediatric Regulation came into force in the EU in 2007. Since then the EMA Paediatric Committee (PDCO) has approved a large number of Paediatric Investigational Plans (PIPs) and an increasing number of applications for paediatric indications have been submitted to EMA and the national regulatory agencies. A revision to the guideline is therefore proposed to reflect the experience gained over the last decade and developments in science.
English (EN) (108.6 KB - PDF)
Document history - First version (current)
Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population
English (EN) (114.35 KB - PDF)
Overview of comments received on the draft guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population
English (EN) (193.34 KB - PDF)
Related content
- Clinical efficacy and safety: clinical pharmacology and pharmacokinetics
- Scientific guidelines: paediatrics
- Directive 2001/83/EC
- Questions and answers: Positions on specific questions addressed to the Pharmacokinetics Working Party
- Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function
- ICH E3 Structure and content of clinical study reports
- ICH E6 (R1) Good clinical practice
- ICH E8 General considerations for clinical trials
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- ICH Q2(R1) Validation of analytical procedures: text and methodology
- Investigation of chiral active substances
- Investigation of bioequivalence
- Investigation of drug interactions
- Pharmacokinetic and clinical evaluation of modified-release dosage forms
- Pharmacokinetic studies in man